IROS, Prilenia dan Asosiasi Penyakit Huntington Internasional berkolaborasi dalam uji coba penyakit Huntington (HD) yang pertama di wilayah MENA

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to plan the first-ever clinical trial Baca lebih lanjut...

uniQure Mengumumkan Pembaruan Data Sementara yang Positif yang Menunjukkan Perlambatan Perkembangan Penyakit pada Uji Coba Tahap I/II AMT-130 untuk HD

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure. “We believe Baca lebih lanjut...

Wave Life Sciences Mengumumkan Hasil Positif dari Uji Coba SELECT-HD Fase 1b/2a dengan Demonstrasi Klinis Pertama dari Penurunan Huntingtin Mutan Selektif Alel pada Penyakit Huntington

Today, Wave Life Sciences announced positive results from SELECT-HD, our Phase 1b/2a placebo-controlled trial evaluating the investigational therapy WVE-003. These results demonstrate that WVE-003 selectively lowers toxic, mutant huntingtin (mHTT) protein and preserves healthy, wild-type huntingtin (wtHTT) protein for individuals Baca lebih lanjut...

id_IDIndonesian
Loncat ke konten